Vitreous haemorrhage in massive hemorrhagic polypoidal choroidal vasculopathy: clinical characteristics and surgical outcomes
© Narayanan et al. 2015
Received: 14 August 2015
Accepted: 2 November 2015
Published: 20 December 2015
To report the outcomes of vitreous hemorrhage (VH) associated with hemorrhagic polypoidal choroidal vasculopathy (PCV).
A retrospective study of 28 eyes of 27 consecutive patients of hemorrhagic PCV with VH, which were managed surgically between January 2003 and December 2011, was performed. All patients underwent pars plana vitrectomy for VH associated with PCV. The main outcome measure was best-corrected visual acuity (BCVA) at baseline, at 1, 3 and 6 months post operatively and at last follow up.
The visual acuity measured on early treatment diabetic retinopathy study (ETDRS) chart improved in 16 eyes (57.1 %) by two or more lines, remained unchanged in nine eyes (32.1 %) and decreased in three (10.7 %) after surgery when compared to baseline VA. The mean baseline VA was 2.69 ± 0.57 logMAR units (<20/2000) which improved to 1.65 ± 0.93 logMAR units (20/800) at 1 month post operative visit and was sustained at 1.72 ± 1.12 (20/800) with an improvement of 0.96 logMAR units (p < 0.001, 95 % CI 0.54–1.37). The average postoperative follow up was for 14.2 months (range 1–84). The complications noted in postoperative follow up were cataract (n = 10), macular scaring (n = 9), organised dehemoglobinised blood (n = 7), retinal tear or detachment (n = 5), recurrent VH (n = 3) and choroidal detachment (n = 1).
Majority of patients with loss of vision due to VH secondary to hemorrhagic PCV have sustained improvement in visual acuity following surgery.
KeywordsPolypoidal choroidal vasculopathy Vitrectomy Vitreous haemorrhage
Polypoidal choroidal vasculopathy (PCV) is a persistent and chronic disease with a variable course . Although the prognosis of PCV is commonly reported to be more favorable and the clinical course more stable as compared with exudative age-related macular degeneration (AMD) [2–4], the natural history of PCV, especially haemorrhagic PCV, is not clearly known and may not be as benign as previously reported .
The primary abnormality in PCV involves the choroidal circulation, and the characteristic lesion is an inner choroidal vascular network of vessels ending in an aneurysmal bulge or outward projection seen clinically as reddish orange polyps . Leakage in the vessel wall at dilatations leads to serous pigment epithelial detachments (PED) and lipid deposition in the exudative form of PCV while recurrent serosanguinous detachments of the retinal pigment epithelium and neurosensory retina are the predominant manifestation of hemorrhagic PCV. Massive hemorrhages may develop from rupture of venules and occasionally arteries. Sequelae of this is a sudden onset severe visual loss due to break through vitreous hemorrhage (VH) [1, 6–10].
About half the cases of PCV have a stable course and relatively favorable visual outcome, while the others have persistent leakage, repeated haemorrhages and poor visual outcome [1, 4]. Profound visual loss in hemorrhagic PCV primarily results from recurrent serosanguinous haemorrhagic detachments involving the fovea or recurrent VH.
There is a lack of understanding of hemorrhagic PCV and there are very few reports in the literature on the outcomes of conservative [1, 4], or surgical management of PCV with VH [4, 6]. In the current study we report the incidence, clinical characteristics, management and surgical outcome in haemorrhagic PCV presenting with vitreous haemorrhage.
This study was a retrospective, interventional consecutive case series. The study was approved by the local ethics committee of L.V. Prasad Eye Institute (LEC-11-160) and all participants gave consent for using patient data for research purpose. Medical records of all cases having a diagnosis ICD coding of PCV and vitreous haemorrhage who underwent pars plana vitrectomy (PPV) were identified and studied. Twenty-eight eyes of 27 consecutive patients treated surgically for PCV associated with VH were included.
Due to the presence of VH, the media clarity did not allow the visualization of the fundus or angiography in most eyes at presentation. Although the EVEREST trial laid down guidelines for the diagnosis of PCV , massive hemorrhagic PCV may not show the same features at presentation in the affected eye. The vitreous haemorrhage was attributed to PCV on the basis of preoperative B-scan features , and confirmed with demonstration of polypoidal lesions and/or branching vascular network in the study or fellow eye on indocyanine angiography (ICGA) in the past or post-operatively, as laid down in the EVEREST trial . Patients were excluded if the same or fellow eye had any other vascular or degenerative retinal or macular condition, or any other ocular pathology which could limit their vision.
After a preoperative written informed consent all patients underwent standard 20 or 23 gauge PPV. Removal of subretinal blood was not attempted in this series.
Demographic and baseline characteristics
No of eyes
58.89 years (range 36–82)
22 males, 6 females
Bilateral PCV + VH
4 (14.28 %)
10 patients/13 years (range 3–25 years)
15 patients/10.5 years (range 1–36 years)
13 OD, 15 OS
Duration of symptoms in months
6.2 (range 1–48 months)
11 phakic, 6 pseudophakic, 1 aphakic
VR surgery (n = 3), IVB (n = 5), PDT (n = 3), Laser (n = 1), IVTA (n = 1), Oral steroids (n = 3)
Fundus exam at presentation
No view (n = 21), hemorrhagic PED (n = 6), subretinal blood (n = 4), pigmentary changes (n = 1)
The primary outcome measure of this series was the number of patients who improved by two or more lines on early treatment diabetic retinopathy study (ETDRS) chart after surgery. Secondary outcome measures were mean change in logMAR visual acuity, and complications of surgery.
The visual improvement post operatively and the differences between BCVA at 1 month post operative visit and final follow up from the baseline pre operative visual acuity were compared using paired t test. Statistical analysis was done using Statistical software R, version 2.14.1.
Twenty-eight eyes of 27 patients (21 men, 6 women) with a mean age of 58.89 ± 13.13 years (range 36–82) underwent PPV for vitreous haemorrhage associated with PCV between January 2003 and December 2011. Their baseline demographic characteristics are shown in Table 1. Ten (37 %) patients had a history of diabetes mellitus for an average of 13 years (range 3–25 years) and 16 (59 %) patients had a history of hypertension for an average 10.5 years (range 1–36).
Surgical management and postoperative outcome
Baseline BCVA at presentation
2.69 ± 0.57 (<20/2000)
BCVA at 1 months postoperative visit improvement from baseline
1.65 (SD 0.93, 20/800, p = 0.001), range 20/20 to no PL, 0.99 logMAR units, (p = < 0.001, 95 % CI 0.64–1.34)
BCVA at 6 months postoperative visit
1.53 (SD 1.2, 20/600, p = 0.0001), range 20/20 to no PL
Improvement from baseline to last visit
0.96 logMAR units, (p < 0.0001, 95 % CI 0.54–1.37)
Mean follow up
14.8 months (range 1–84 months)
BCVA improved by two lines or more than presenting VA at last follow up
16 of 28 eyes (57.1 %)
BCVA worsened at last follow up than baseline BCVA
3 of 28 eyes (10.7 %)
Cataract (n = 10), macular scar (n = 4), organised dehemoglobinised blood/exudates (n = 7), retinal detachment (n = 5), iatrogenic retinal breaks (n = 5), recurrent VH (n = 3), choroidal detachment (n = 1)
Prior to surgery, five study eyes had been treated with intravitreal bevacizumab, one received intravitreal triamcinolone, three had undergone focal laser treatment, two eyes had undergone sclera buckling in the same eye in the past and three eyes had a history of photo dynamic therapy (PDT). Three patients in whom B-scan showed exudative retinal detachment were treated with oral steroids preoperatively. Nine (33.3 %) patients had bilateral PCV of which four (14.8 %) also had associated VH with PCV in the fellow eye.
The site of subretinal haemorrhage was found to be predominantly macular in 12 (42.8 %) eyes, peripapillary in 4 (14.2 %) eyes, midperipheral in 10 (35.7 %) eyes and peripheral in 1 (3.5 %) eye. Intraoperatively, macular scar was noted in 9 (32.1 %) eyes and organized dehemoglobinized blood at the macula was noted in seven (25 %) eyes.
The most common surgical complication was iatrogenic retinal break which was seen in 5 (17.8 %) eyes, which occurred typically during induction of posterior vitreous detachment (PVD). Postoperatively, 10 (35.7 %) eyes developed visually significant cataract, 3 (10.7 %) eyes developed recurrent vitreous haemorrhage, 5 (17.8 %) had retinal detachment and 1 (3.5 %) patient had choroidal detachment. The mean IOP at baseline was 13.64 ± 2.52 and 13.57 ± 4.12 mm Hg at the last follow up.
Several reports and case series describing the diverse clinical spectrum, natural course, and role of various modalities of treatments for exudative PCV have been published in the last three decades [1, 2, 6–9, 11, 12], but there are few reports in the literature on the management of vitreous haemorrhage associated with PCV [6, 8, 9, 13]. Vitreous haemorrhage associated with PCV differs from other manifestations of PCV as these eyes are not amenable to ICG angiography. Unless the affected eye has been previously diagnosed as PCV or the fellow eye has features of PCV, it is difficult to diagnose them. B-scan features that can differentiate vitreous haemorrhage secondary to PCV from other causes has been reported and are very useful in this situation. B-scan can demonstrate defining features like blood lining an elevated membrane, hemorrhagic pigment epithelial detachment and absence of any acoustic shadowing. The natural course or role of any treatment modality is unknown for vitreous haemorrhage in PCV as no large series of cases has been studied.
In our study, PCV was bilateral in 9 (33.3 %) of which four eyes (14.8 %) also had PCV associated vitreous haemorrhage in the fellow eye. Previously, bilaterality has been reported ranging from 9 to 47 % for exudative PCV [1, 8, 9, 12, 14]. PCV had been originally reported in hypertensive middle aged African women [8, 14–16]. Associated systemic hypertension has been reported in 18–88 % in various case series and clinic pathological studies of PCV [8, 9, 14]. In our series, 59 % of the patients had systemic hypertension.
Vitreous haemorrhage associated with PCV has also been reported to occur following PDT [7, 17]. In our series only one patient had history of recent PDT and developed sudden onset loss of vision and VH 1 week after the treatment.
The earliest descriptions of vitreous haemorrhage in PCV was in 1985 [9, 10]. In previous reports by Kleiner et al. and Perkovich et al. [8, 9], visual recovery after vitrectomy was found to be equivocal. Two of the three eyes gained useful vision in one series , whereas the other studies reported worsening or no change in the visual acuity [4, 9]. These studies had small series ranging from one to three eyes that underwent vitrectomy. Recent reported outcomes of vitrectomy in PCV did not find a higher incidence of retinal breaks [13, 18].
In our study, significant visual improvement occurred in 16 of 29 eyes (57.1 %). Three patients recovered a visual acuity of better than 20/40, one eye had a visual acuity of 20/20 at 84 months, another had 20/25 at 17 months and the third eye had 20/40 at 6 months follow up. The improvement in visual acuity could have been limited by extensive blood under the macula. We did not attempt to remove the subretinal blood in our study. All cases in our study would have required subretinal tissue plasminogen activator with incubation of approximately half an hour. In our experience, the blood decolorizes rapidly in these cases and does not liquefy with conventional doses of tPA. In such cases, the dose of tPA is much more than the recommended upper limit of 50 μg. Further, washing of blood in such massive hemorrhage under the macula tends to cause photoreceptor damage. The peripheral visual field would also have improved after the clearance of vitreous haemorrhage but would be difficult to document in most cases due to poor central fixation.
The commonest intra operative complication was iatrogenic retinal breaks, which occurred during induction of PVD which was also been reported by us in our previous study . Hence it is possibly better to wait for spontaneous PVD to occur before attempting surgery. The cases which had no visual recovery or experienced worsening of vision had macular scar, recurrent VH, post operative retinal detachment and cataract.
In a few cases in our study, polypoidal lesions which were seen on ICG-A before vitreous haemorrhage were not seen postoperatively but new lesions polypoidal lesions developed in a new location on subsequent follow up (Fig. 3). This disappearance of classic polypoidal lesions and replacement by RPE atrophy and scarring has been described in previously reported cases [1, 9]. The development of the haemorrhagic PEDs from the pre-existing polypoidal lesions, followed by breakthrough VH and then subsequent scarring may be the natural course of the condition.
Our study shows that vitrectomy can produce significant visual improvement in patients with vitreous haemorrhage due to PCV. The incidence of retinal breaks during vitrectomy is high in PCV, and caution should be exercised while inducing PVD in such cases.
age-related macular degeneration
best-corrected visual acuity
early treatment diabetic retinopathy study
pars plana vitrectomy
perception of light
photo dynamic therapy
pigment epithelial detachments
polypoidal choroidal vasculopathy
posterior vitreous detachment
Design and conduct of the study (RN), collection, management, analysis, and interpretation of the data (RN, KM, HA), and preparation, review, or approval of the manuscript (RN, SJ, JC, ANM, KM). All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Uyama M, Mitsumasa W, Nagai Y, Matsubara T, et al. Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol. 2002;133:639–48.PubMedView ArticleGoogle Scholar
- Yannuzzi LA, Ciardella A, Spaide RF, et al. The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol. 1997;115:478–85.PubMedView ArticleGoogle Scholar
- Moorthy RS, Lyon AT, Rabb MF, et al. Idiopathic choroidal vasculopathy of the macula. Ophthalmology. 1998;105:1380–5.PubMedView ArticleGoogle Scholar
- Lip P, Hope-Ross MW, Gibson JM. Idiopathic polypoidal choroidal vasculopathy: a disease with diverse clinical spectrum and systemic associations. Eye. 2000;14:695–700.PubMedView ArticleGoogle Scholar
- Ciarcella AP, Donsoff IM, Huang SJ, Costa DL, Yannuzzi LA. Polypoidal choroidal vasculopathy: major review. Surv Ophthalmol. 2004;49:25–37.View ArticleGoogle Scholar
- Jalali S, Parra SL, Majji AB, Hussain N, Shah V. Ultrasonographic characteristics and treatment outcomes of surgery for vitreous hemorrhage in idiopathic polypoidal choroidal vasculopathy. Am J Ophthalmol. 2006;142:608–19.PubMedView ArticleGoogle Scholar
- Rishi P, Kadekar A, Rishi E. Breakthrough vitreous hemorrhage after ICGA guided PDT for PCV. Indian J Ophthalmol. 2009;57:160–1.PubMedPubMed CentralView ArticleGoogle Scholar
- Perkovich BT, Zakov ZN, Berlin LA, et al. An update on multiple serosanguinous retinal pigment epithelial detachments in black women. Retina. 1990;10:18–26.PubMedView ArticleGoogle Scholar
- Kleiner RC, Brucker AJ, Johnston RL. The posterior uveal bleeding syndrome. Retina. 1990;10:9–17.PubMedView ArticleGoogle Scholar
- Stern RM, Zakov ZN, Zegerra H, et al. Multiple recurrent serosanguineous retinal pigment epithelial detachments in black women. Am J Ophthalmol. 1985;100:560–9.PubMedView ArticleGoogle Scholar
- Shiraga F, Matsuo T, Yokoe S, et al. Surgical treatment of submacular hemorrhage associated with idiopathic polypoidal choroidal vasculopathy. Am J Ophthalmol. 1999;128:147–54.PubMedView ArticleGoogle Scholar
- Yamaoka S, Okada AA, Sugahara M, Hida T. Clinical features of polypoidal choroidal vasculopathy and visual outcomes in the absence of classic choroidal neovascularisation. Ophthalmologica. 2010;224:147–52.PubMedView ArticleGoogle Scholar
- Jung JH, Lee JK, Lee JE, Oum BS. Results of vitrectomy for breakthrough vitreous hemorrhage associated with age-related macular degeneration and polypoidal choroidal vasculopathy. Retina. 2010;30(6):865–73.PubMedView ArticleGoogle Scholar
- Ahuja RM, Stanga PE, Johannes RV, Rech AC, Bird AC. Polypoidal vasculopathy in exudative and hemorrhagic pigment epithelial detachments. Br J Ophthalmol. 2000;84:479–84.PubMedPubMed CentralView ArticleGoogle Scholar
- Ross RD, Glitter KA, Cohen G, Shomaker KS. Idiopathic polypoidal choroidal vasculopathy associated with retinal macroaneurysm and hypertensive retinopathy. Retina. 1996;16:105–11.PubMedView ArticleGoogle Scholar
- Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 1990;10:1–8.PubMedView ArticleGoogle Scholar
- Ojima Y, Tsujikawa A, Otani A, Hirami Y, Aikawa H, Yoshimura N. Recurrent bleeding after photodyanamic therapy in polypoidal choroidal vasculopathy. Am J Ophthal. 2006;141:958–60.PubMedView ArticleGoogle Scholar
- Lin HC, Yang CH, Yang CM. Visual outcomes of vitrectomy for polypoidal choroidal vasculopathy-related breakthrough vitreous haemorrhage. Eye (Lond). 2014;28(7):797–806.View ArticleGoogle Scholar